- Home
- Â /Â Puma Biotechnology
Puma Biotechnology
Stock Price
$2.8
2024-10-29
Market Capitalization
$136.8 M
2024-10-29
Revenue
$235.6 M
FY, 2023
Puma Biotechnology Summary
Company Summary
- Overview
- Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. Its focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Los Angeles, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Douglas Hunt, Senior Vice President, Regulatory Affairs, Medical Writing and Project Management
Maximo F. Nougues, Chief Financial Officer
Jeff J. Ludwig, Chief Commercial Officer
Puma Biotechnology Financials
Summary Financials
- Revenue (Q3, 2024)
- $80.5M
- Gross profit (Q3, 2024)
- $51.4M
- Net income (Q3, 2024)
- $20.3M
- Cash (Q3, 2024)
- $67.3M
- EBIT (Q3, 2024)
- $22.1M
- Enterprise value
- $147.7M